Design, Optimization and Characterization of Gemcitabine - Loaded Cubosomes for Treatment of Breast Cancer in MCF-7 Cell Lines

Sunil T. Galatage; Abdulfattah Y. Alhazmi; Maha M. Albazi; Abeer A. Banjabi; Abdulkarim S. Binshaya; Mater H. Mahnashi; Ibrahim Ahmed Shaikh; Uday M. Muddapur; Omaish Alqahtani; Arehalli S. Manjappa; Vijay M. Kumbar; Amolkumar Kempwade; Shashikant M. Adasule; Ashish M. Phutane; Samruddhi S. Kadam; Shruti R. Mandekar; Aejaz Abdullatif Khan; Rushikesh S. Sansare; Shweta N. Kalebere

Design, Optimization and Characterization of Gemcitabine - Loaded Cubosomes for Treatment of Breast Cancer in MCF-7 Cell Lines

Sunil T. Galatage, Abdulfattah Y. Alhazmi, Maha M. Albazi, Abeer A. Banjabi, Abdulkarim S. Binshaya, Mater H. Mahnashi, Ibrahim Ahmed Shaikh, Uday M. Muddapur, Omaish Alqahtani, Arehalli S. Manjappa, Vijay M. Kumbar, Amolkumar Kempwade, Shashikant M. Adasule, Ashish M. Phutane, Samruddhi S. Kadam, Shruti R. Mandekar, Aejaz Abdullatif Khan, Rushikesh S. Sansare, Shweta N. Kalebere

Medical Laboratory Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Current research work aimed to design, characterize and optimize gemcitabine (GCB) cubo-somes for the effective treatment of breast cancer. Cubosomes were developed by using solvent evaporation technique and optimized using 3² Factorial design to verify effect vesicle size and entrapment efficiency using poloxamer-407 (P-407) as emulsifier and glyceryl monooleate (GMO) as lipid. The optimized GCB cubo-somes were characterized for morphology by transmission electron microscope (TEM), crystalline by X-ray diffraction (XRD), in vitro release, in vitro cytotoxicity, apoptotic potential, etc. Optimized GCB cubosomes have a mean vesicle size of 184.2±3 nm with PDI 0.230± 0.046, zeta potential-28.1±2.73 mV, and entrapped 94.48± 4.54 % of GCB. Furthermore, the GCB cubosomes demonstrated significantly (p < 0.01) higher in vitro cytotoxic and apoptotic activity against breast cancer (MCF-7) cells after 48 hr of incubation. Hence, the developed GCB cubosomes can be used as a competent alternative to systemic chemotherapy in the effective management of breast cancer.

Original language	English
Pages (from-to)	1369-1380
Number of pages	12
Journal	Latin American Journal of Pharmacy
Volume	42
Issue number	7
State	Published - 2023

Keywords

apoptosis
breast cancer
cubosomes
cytotoxicity
gemcitabine
Polaxomer-407

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Galatage, S. T., Alhazmi, A. Y., Albazi, M. M., Banjabi, A. A., Binshaya, A. S., Mahnashi, M. H., Shaikh, I. A., Muddapur, U. M., Alqahtani, O., Manjappa, A. S., Kumbar, V. M., Kempwade, A., Adasule, S. M., Phutane, A. M., Kadam, S. S., Mandekar, S. R., Khan, A. A., Sansare, R. S., & Kalebere, S. N. (2023). Design, Optimization and Characterization of Gemcitabine - Loaded Cubosomes for Treatment of Breast Cancer in MCF-7 Cell Lines. Latin American Journal of Pharmacy, 42(7), 1369-1380.

@article{6d2be81d161a4086aa20c204dc091a69,

title = "Design, Optimization and Characterization of Gemcitabine - Loaded Cubosomes for Treatment of Breast Cancer in MCF-7 Cell Lines",

abstract = "Current research work aimed to design, characterize and optimize gemcitabine (GCB) cubo-somes for the effective treatment of breast cancer. Cubosomes were developed by using solvent evaporation technique and optimized using 32 Factorial design to verify effect vesicle size and entrapment efficiency using poloxamer-407 (P-407) as emulsifier and glyceryl monooleate (GMO) as lipid. The optimized GCB cubo-somes were characterized for morphology by transmission electron microscope (TEM), crystalline by X-ray diffraction (XRD), in vitro release, in vitro cytotoxicity, apoptotic potential, etc. Optimized GCB cubosomes have a mean vesicle size of 184.2±3 nm with PDI 0.230± 0.046, zeta potential-28.1±2.73 mV, and entrapped 94.48± 4.54 \% of GCB. Furthermore, the GCB cubosomes demonstrated significantly (p < 0.01) higher in vitro cytotoxic and apoptotic activity against breast cancer (MCF-7) cells after 48 hr of incubation. Hence, the developed GCB cubosomes can be used as a competent alternative to systemic chemotherapy in the effective management of breast cancer.",

keywords = "apoptosis, breast cancer, cubosomes, cytotoxicity, gemcitabine, Polaxomer-407",

author = "Galatage, \{Sunil T.\} and Alhazmi, \{Abdulfattah Y.\} and Albazi, \{Maha M.\} and Banjabi, \{Abeer A.\} and Binshaya, \{Abdulkarim S.\} and Mahnashi, \{Mater H.\} and Shaikh, \{Ibrahim Ahmed\} and Muddapur, \{Uday M.\} and Omaish Alqahtani and Manjappa, \{Arehalli S.\} and Kumbar, \{Vijay M.\} and Amolkumar Kempwade and Adasule, \{Shashikant M.\} and Phutane, \{Ashish M.\} and Kadam, \{Samruddhi S.\} and Mandekar, \{Shruti R.\} and Khan, \{Aejaz Abdullatif\} and Sansare, \{Rushikesh S.\} and Kalebere, \{Shweta N.\}",

year = "2023",

language = "English",

volume = "42",

pages = "1369--1380",

journal = "Latin American Journal of Pharmacy",

issn = "0326-2383",

publisher = "Colegio de Farmaceuticos de la Provincia de Buenos Aires",

number = "7",

}

Galatage, ST, Alhazmi, AY, Albazi, MM, Banjabi, AA, Binshaya, AS, Mahnashi, MH, Shaikh, IA, Muddapur, UM, Alqahtani, O, Manjappa, AS, Kumbar, VM, Kempwade, A, Adasule, SM, Phutane, AM, Kadam, SS, Mandekar, SR, Khan, AA, Sansare, RS & Kalebere, SN 2023, 'Design, Optimization and Characterization of Gemcitabine - Loaded Cubosomes for Treatment of Breast Cancer in MCF-7 Cell Lines', Latin American Journal of Pharmacy, vol. 42, no. 7, pp. 1369-1380.

TY - JOUR

T1 - Design, Optimization and Characterization of Gemcitabine - Loaded Cubosomes for Treatment of Breast Cancer in MCF-7 Cell Lines

AU - Galatage, Sunil T.

AU - Alhazmi, Abdulfattah Y.

AU - Albazi, Maha M.

AU - Banjabi, Abeer A.

AU - Binshaya, Abdulkarim S.

AU - Mahnashi, Mater H.

AU - Shaikh, Ibrahim Ahmed

AU - Muddapur, Uday M.

AU - Alqahtani, Omaish

AU - Manjappa, Arehalli S.

AU - Kumbar, Vijay M.

AU - Kempwade, Amolkumar

AU - Adasule, Shashikant M.

AU - Phutane, Ashish M.

AU - Kadam, Samruddhi S.

AU - Mandekar, Shruti R.

AU - Khan, Aejaz Abdullatif

AU - Sansare, Rushikesh S.

AU - Kalebere, Shweta N.

PY - 2023

Y1 - 2023

N2 - Current research work aimed to design, characterize and optimize gemcitabine (GCB) cubo-somes for the effective treatment of breast cancer. Cubosomes were developed by using solvent evaporation technique and optimized using 32 Factorial design to verify effect vesicle size and entrapment efficiency using poloxamer-407 (P-407) as emulsifier and glyceryl monooleate (GMO) as lipid. The optimized GCB cubo-somes were characterized for morphology by transmission electron microscope (TEM), crystalline by X-ray diffraction (XRD), in vitro release, in vitro cytotoxicity, apoptotic potential, etc. Optimized GCB cubosomes have a mean vesicle size of 184.2±3 nm with PDI 0.230± 0.046, zeta potential-28.1±2.73 mV, and entrapped 94.48± 4.54 % of GCB. Furthermore, the GCB cubosomes demonstrated significantly (p < 0.01) higher in vitro cytotoxic and apoptotic activity against breast cancer (MCF-7) cells after 48 hr of incubation. Hence, the developed GCB cubosomes can be used as a competent alternative to systemic chemotherapy in the effective management of breast cancer.

AB - Current research work aimed to design, characterize and optimize gemcitabine (GCB) cubo-somes for the effective treatment of breast cancer. Cubosomes were developed by using solvent evaporation technique and optimized using 32 Factorial design to verify effect vesicle size and entrapment efficiency using poloxamer-407 (P-407) as emulsifier and glyceryl monooleate (GMO) as lipid. The optimized GCB cubo-somes were characterized for morphology by transmission electron microscope (TEM), crystalline by X-ray diffraction (XRD), in vitro release, in vitro cytotoxicity, apoptotic potential, etc. Optimized GCB cubosomes have a mean vesicle size of 184.2±3 nm with PDI 0.230± 0.046, zeta potential-28.1±2.73 mV, and entrapped 94.48± 4.54 % of GCB. Furthermore, the GCB cubosomes demonstrated significantly (p < 0.01) higher in vitro cytotoxic and apoptotic activity against breast cancer (MCF-7) cells after 48 hr of incubation. Hence, the developed GCB cubosomes can be used as a competent alternative to systemic chemotherapy in the effective management of breast cancer.

KW - apoptosis

KW - breast cancer

KW - cubosomes

KW - cytotoxicity

KW - gemcitabine

KW - Polaxomer-407

UR - http://www.scopus.com/inward/record.url?scp=85164384791&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85164384791

SN - 0326-2383

VL - 42

SP - 1369

EP - 1380

JO - Latin American Journal of Pharmacy

JF - Latin American Journal of Pharmacy

IS - 7

ER -

Design, Optimization and Characterization of Gemcitabine - Loaded Cubosomes for Treatment of Breast Cancer in MCF-7 Cell Lines

Abstract

Keywords

UN SDGs

Other files and links

Fingerprint

Cite this